Added to YB: 2026-03-03
Pitch date: 2026-02-27
GSK [neutral]
GSK plc
-0.64%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 88.3B
Pitch Price
GBP 21.94
Price Target
N/A
Dividend
3.27%
EV/EBITDA
7.73
P/E
15.86
EV/Sales
3.13
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 27/2/2026 - GSK – Acquisition and pipeline progress
GSK (update): Acquired 35Pharma for $950M cash to enter $18B pulmonary hypertension market. Linerixibat accepted for priority review in China (280K patient market). Bepirovirsen under review in Japan for chronic Hep B (1M patients). Stock +20% YTD but still trades 12.1x fwd P/E.
Read full article (1 min)